Effects of switching to low-dose rosuvastatin (5mg/day) on glucose metabolism and lipid profiles in Japanese patients with type 2 diabetes and dyslipidemia: a single-arm, prospective, interventional trial.

Abstract

We investigated the effects of switching from other statins, such as pravastatin (5 or 10mg/day), rosuvastatin (2.5mg/day), or pitavastatin (1 or 2mg/day), to low-dose rosuvastatin (5mg/day) on glucose metabolism and lipid profiles in Japanese patients with type 2 diabetes and dyslipidemia. This was a prospective, two-center, open-label, single-arm, interventional trial. Several clinical parameters were analyzed at baseline and 24weeks after switching from other statins to rosuvastatin at 5mg/day. The primary endpoints were changes in hemoglobin (Hb) A1c level and lipid profile. Forty-five patients were enrolled in the trial. The mean HbA1c level increased significantly from 7.1±0.7 to 7.5±0.9% (P<0.001), whereas the mean low-density lipoprotein cholesterol (LDL-C) level decreased significantly from 108.9±16.5 to 91.6±24.5mg/dL (P<0.001). Multiple linear regression analysis showed that changes in HbA1c levels were significantly and positively correlated with fasting plasma glucose (FPG) levels at baseline. Receiver operating characteristic (ROC) curve analysis examining the relationship between HbA1c and FPG showed that FPG was a significant predictor of changes in HbA1c levels (area under the curve, 0.72). The cutoff FPG value of 168mg/dL had a sensitivity of 47% and a specificity of 93%. Switching to a low dose of rosuvastatin impaired glucose metabolism in Japanese patients with type 2 diabetes and dyslipidemia. Patients with high FPG levels were particularly prone to an exacerbation of glucose metabolism.